Candel Therapeutics Announces Initial Interim Data from Randomized Phase 2 Clinical Trial Of CAN-2409 In Non-Metastatic Pancreatic Cancer
Portfolio Pulse from Benzinga Newsdesk
Candel Therapeutics announced positive interim data from a randomized Phase 2 clinical trial of CAN-2409 in non-metastatic pancreatic cancer. The data showed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after treatment with CAN-2409. The overall survival rate was 71.4% at 36 months in CAN-2409 treated patients versus 16.7% in the control arm. Safety analysis demonstrated that multiple injections of CAN-2409 were generally well tolerated.
November 03, 2023 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Candel Therapeutics' positive interim data from the Phase 2 trial of CAN-2409 could potentially boost investor confidence and the company's stock price in the short term.
The positive interim data from the Phase 2 trial of CAN-2409 indicates that the drug is effective and safe. This could potentially lead to regulatory approval and commercialization, which would increase the company's revenues and profitability. As a result, investor confidence in the company could increase, leading to a rise in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100